Faster access than browser!
14 relations: ABT-436, Adjuvant therapy, Balovaptan, Binding selectivity, Clinical trial, List of investigational antidepressants, Major depressive disorder, Nelivaptan, Oral administration, Receptor antagonist, SRX246, Taisho Pharmaceutical Co., Vasopressin, Vasopressin receptor 1B.
ABT-436
ABT-436 is an orally active, highly selective vasopressin V1B receptor antagonist which was under development by Abbott Laboratories and AbbVie for the treatment of major depressive disorder, anxiety disorders, and alcoholism but was discontinued.
New!!: TS-121 and ABT-436 · See more »
Adjuvant therapy
Adjuvant therapy, also known as adjunct therapy, add-on therapy, and adjuvant care, is therapy that is given in addition to the primary or initial therapy to maximize its effectiveness.
New!!: TS-121 and Adjuvant therapy · See more »
Balovaptan
Balovaptan (developmental code names RG7314, RO5028442), is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of autism.
New!!: TS-121 and Balovaptan · See more »
Binding selectivity
Binding selectivity is defined with respect to the binding of ligands to a substrate forming a complex.
New!!: TS-121 and Binding selectivity · See more »
Clinical trial
Clinical trials are experiments or observations done in clinical research.
New!!: TS-121 and Clinical trial · See more »
List of investigational antidepressants
This is a list of investigational antidepressants, or antidepressants that are currently under development for clinical use in the treatment of mood disorders but are not yet approved.
New!!: TS-121 and List of investigational antidepressants · See more »
Major depressive disorder
Major depressive disorder (MDD), also known simply as depression, is a mental disorder characterized by at least two weeks of low mood that is present across most situations.
New!!: TS-121 and Major depressive disorder · See more »
Nelivaptan
Nelivaptan (INN) (developmental codename SSR-149,415) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype.
New!!: TS-121 and Nelivaptan · See more »
Oral administration
| name.
New!!: TS-121 and Oral administration · See more »
Receptor antagonist
A receptor antagonist is a type of receptor ligand or drug that blocks or dampens a biological response by binding to and blocking a receptor rather than activating it like an agonist.
New!!: TS-121 and Receptor antagonist · See more »
SRX246
SRX246, also known as API-246, is a small-molecule, centrally-active, highly-selective vasopressin V1A receptor antagonist which is under investigation by Azevan Pharmaceuticals for the treatment of affective and anger disorders.
New!!: TS-121 and SRX246 · See more »
Taisho Pharmaceutical Co.
() is a Japanese pharmaceutical company based in Tokyo.
New!!: TS-121 and Taisho Pharmaceutical Co. · See more »
Vasopressin
Vasopressin, also named antidiuretic hormone (ADH), arginine vasopressin (AVP) or argipressin, is a hormone synthesized as a peptide prohormone in neurons in the hypothalamus, and is converted to AVP.
New!!: TS-121 and Vasopressin · See more »
Vasopressin receptor 1B
Vasopressin V1b receptor (V1BR) also known as vasopressin 3 receptor (VPR3) or antidiuretic hormone receptor 1B is a protein that in humans is encoded by the AVPR1B (arginine vasopressin receptor 1B) gene.
New!!: TS-121 and Vasopressin receptor 1B · See more »
Redirects here:
TS 121, TS 1211, TS-1211, TS121, TS1211.
